Healthcare Analysts Weigh In on Two Biotech Stocks: MannKind Corporation (MNKD), Amarin Corporation plc (ADR) (AMRN)

MannKind Corporation

Piper Jaffray analyst Joshua Schimmer weighed in on shares of MannKind Corporation (NASDAQ:MNKD) after the company’s founder passed away today at the age of 90.

Schimmer wrote, “We’ve known Mr. Mann for nearly a decade and were always impressed at his amazing track record as well as his stamina for business. His career started in aerospace in the 1950’s, then he ventured into pacemakers and insulin pumps (MiniMed) in the 90’s, and subsequently neuroprosthetics (cochlear implants with Advanced Bionics, retinal prosthesis with Second Sight), and then inhaled insulin/Afrezza with MNKD. His company, Bioness, was what got us truly interested in the field of neuromodulation, with important lessons that we apply today to other companies we cover. While not every one of his companies proved to be a commercial success, he leaves behind one of the most impressive contributions to technology development the world has ever seen.”

“Regardless, not all accomplishments in life are measured by stock valuation, and regardless of our very low PT on MNKD given its financial challenges ahead, we’ve always been a big fan of Al Mann,” the analyst continued.

According to, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joshua Schimmer has a yearly average return of -23.8% and a 17% success rate. Schimmer has a 19% average return when recommending MNKD, and is ranked #3673 out of 3,730 analysts.

Amarin Corporation plc (ADR)

In a research report released Friday, H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on shares of Amarin Corporation plc (ADR) (NASDAQ:AMRN) , with a price target of $10, following yesterday’s earning call and management’s broad guidance.

The analyst provided his input on Amarin’s on-going REDUCE-IT study: “We have previously written extensively on our own projections exploring the interplay between event rates and readout timeline for both the interim analysis and the full study analysis. Now, following management’s emphasis on a potentially prolonged data analysis timeframe due to the need to adjudicate MACE primary events and the large-scale, international reach of the study, we find it prudent to conservatively extend our own projected data analysis timeframe by 2 months while maintaining our assumptions on the primary events trajectory itself.”

“Ahead of the expected heightened volatility, volume and likely share price appreciation, we believe, leading into the interim readout event this year, we reiterate our Buy rating,” the analyst concluded.

According to, analyst Andrew Fein has a yearly average return of -4.9% and a 36.7% success rate. Fein has a -39.9% average return when recommending AMRN, and is ranked #3230 out of 3730 analysts.

Out of the 3 analysts polled by TipRanks, 2 rate Amarin stock a Buy, while 1 rates the stock a Hold. With a return potential of 365.5%, the stock’s consensus target price stands at $6.75.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts